Compare · BDX vs KIDS
BDX vs KIDS
Side-by-side comparison of Becton Dickinson and Company (BDX) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $40.60B, about 88.7x KIDS ($458.0M).
- Over the past year, BDX is down 16.2% and KIDS is down 17.6% - BDX leads by 1.3 points.
- KIDS has been more active in the news (12 items in the past 4 weeks vs 11 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- Becton Dickinson and Company
- OrthoPediatrics Corp.
- Price
- $146.12-0.86%
- $18.00+0.87%
- Market cap
- $40.60B
- $458.0M
- 1M return
- +1.35%
- +1.64%
- 1Y return
- -16.24%
- -17.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 11
- 12
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest BDX
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest KIDS
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
- Director Fischer Kelly Laine was granted 11,436 shares, increasing direct ownership by 263% to 15,781 units (SEC Form 4)
- Director Ruf Harold was granted 11,436 shares, increasing direct ownership by 136% to 19,837 units (SEC Form 4)
- Director Hughes Bryan W was granted 11,436 shares, increasing direct ownership by 54% to 32,663 units (SEC Form 4)
- Director Riccitelli Samuel D was granted 11,436 shares, increasing direct ownership by 56% to 31,859 units (SEC Form 4)
- Director Dyer George Sinclair Mitchell was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Mcdonald Jimmy Duane was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Throdahl Mark C was granted 11,436 shares, increasing direct ownership by 7% to 179,317 units (SEC Form 4)
- President and CEO Bailey David R was granted 119,140 shares, increasing direct ownership by 40% to 417,160 units (SEC Form 4)
- Director Infante (Reynolds) Marie C was granted 11,436 shares, increasing direct ownership by 58% to 31,202 units (SEC Form 4)